{"entity":{"id":"nct07811193","kind":"trial","name":"A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum","aka":[],"tldr":"A phase 2 trial of Pembrolizumab in colorectal cancer, run by Vividion Therapeutics, Inc., now recruiting.","summary":"A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum is a phase 2 interventional study registered as NCT07811193 by Vividion Therapeutics, Inc., with 140 participants planned, started 2026-09-11 and due to reach its primary completion in 2028-06-30. Interventions recorded: VVD-133214 and Pembrolizumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07811193","url":"https://clinicaltrials.gov/study/NCT07811193"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal","msi-high-colorectal","rectal-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":["bayer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07811193","phase":"2","setting":"A Phase 2, Randomized, Open-label Study of VVD-133214 in COmbination With Pembrolizumab Compared to Pembrolizumab Monotherapy in Participants With Advanced Colorectal Adenocarcinoma (CRC) Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (DMMR)","sponsor":"Vividion Therapeutics, Inc.","participation":[{"nct":"NCT07811193","source":"https://clinicaltrials.gov/study/NCT07811193","fetchedAt":"2026-10-07T16:56:52.065Z","studySha256":"39e711b8fd82c04d25902449872c83a7035ecea837876ad567cb9ba1c25cc8c8","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-16","leadSponsor":"Vividion Therapeutics, Inc.","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":140,"enrolmentType":"ESTIMATED","siteCount":122,"recruitingSiteCount":1,"countries":["Argentina","Belgium","Brazil","China","France","Germany","Greece","Hong Kong","Italy","Malaysia","Mexico","Netherlands","Poland","Portugal","Singapore","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2026-09-11","startedType":"actual","enrolled":140,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07811193/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"bayer","kind":"company","name":"Bayer","route":"/companies/bayer/"}]}}